Adverse events · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
Intervention not reported
Adverse events · adolescents (aged 12‐17 years) being overweight or obese
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity
1 finding from 1 review
Intervention not reported
Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death during study period · adults with antisocial personality disorder
It is very uncertain whether psychosocial risk management ('Resettle' programme) changes adverse events: death during the study period Timing of assessment:… compared with treatment‐as‐usual (very low certainty).
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD
It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review